Compare Cronos Group Inc (CRON) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs EPAM Systems Inc — how do they compare? Cronos Group Inc trades at $2.76 (market cap $1.02B), while EPAM Systems Inc trades at $85.52 (market cap $4.41B). The key difference: EPAM Systems Inc is far larger — about 4.3× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| CRON | EPAM | |
|---|---|---|
Market Cap | $1.02B | $4.41B |
Sector | Health | Technology |
52-Week High | $3.27 | $221.40 |
52-Week Low | $1.95 | $76.04 |
Enterprise Value | $203.29M | $3.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
EPAM trades at $86.38, up 2.97% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 12.41 and P/S of 0.86, supported by consistent earnings beats in recent quarters. Revenue grew to $5.46B in 2025, though net income margin dipped to 6.96%. Recent news highlights EPAM's AI partnerships and upcoming Q2 earnings, with analyst sentiment strongly bullish.
The outlook for EPAM is positive given its low valuation multiples and strong analyst consensus, with a price target of $128.55 implying significant upside. Risks include competitive pressures in IT services and potential margin compression, but the company's focus on AI transformation and solid cash flow generation provide a foundation for growth. Investors should weigh the high institutional confidence against macroeconomic headwinds affecting the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
